FOSUN PHARMA Subsidiary Receives Clinical Trial Approval for HLX319 Drug

Stock News04-01

FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities recently obtained approval from the National Medical Products Administration. The approval permits Phase I clinical trials of HLX319, a biosimilar of pertuzumab and trastuzumab injection for subcutaneous use, for neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. Henlius plans to conduct related clinical studies in China once conditions are met. HLX319 is a biosimilar independently developed by the group, composed of active ingredients trastuzumab and pertuzumab, along with the excipient hyaluronidase (HLXTE-HAase02, a novel recombinant human hyaluronidase developed by the group). It is intended for adjuvant/neoadjuvant treatment of early breast cancer and treatment of metastatic breast cancer. As of February 2026, the group's cumulative R&D investment in HLX319 amounts to approximately RMB 33.87 million (unaudited).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment